CME: 1 point
Deadline: 20 January 2025
Remark: You must complete both Part 1 and Part 2 in order to get CME 1 point
The World Health Organization (WHO) defines healthy ageing as the process of developing and maintaining the functional ability that enables wellbeing in older age.
CME: 1 point
Deadline: 20 January 2025
Remark: You must complete both Part 1 and Part 2 in order to get CME 1 point
The World Health Organization (WHO) defines healthy ageing as the process of developing and maintaining the functional ability that enables wellbeing in older age.
AQUIPTA® (Atogepant) ABBVIE HK Reg. No. HK-68287 (03 Jul, 2024) & HK-68288 (03 Jul, 2024) Composition: 1 Aquipta® (Atogepant) is an orally administered, small molecule, selective calcitonin gene-related peptide (CGRP) receptor antagonist...
ANAGRELIDE SANDOZ® (Anagrelide hydrochloride) NOVARTIS HK Reg. No. HK-68231 Composition: 2 ANAGRELIDE SANDOZ® (anagrelide hydrochloride) is an inhibitor of cyclic AMP phosphodiesterase III. It is available in 0.5 mg hard capsule. Indication:...
Multiple myeloma (MM) is a clonal plasma cell disorder characterised by excess production of monoclonal immunoglobulins and light chains that can ultimately lead to specific end-organ damage 1 . Notably, MM is the second most common haematologic mal...
Rabies is a zoonotic, and progressive neurological infection caused by Lyssavirus, affecting both animals and humans. Notably, more than 99% of human rabies are transmitted by unvaccinated dogs, and the disease affects more than 100 countries global...
TARGRETIN™ (bexarotene) MAIN LIFE HK Reg. No. HK-68294 (04 Jul, 2024) Composition: 1 Targretin™ (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). Targretin™ is available in c...
LEQEMBI® (lecanemab) EISAI HK Reg. No. HK-68289 (03 Jul, 2024) & HK-68290 (03 Jul, 2024) Composition: 3 LEQEMBI® is an amyloid beta-directed antibody with the active ingredient lecanemab-irmb. It is administered as an intravenous infusio...
AKEEGA™ (niraparib and abiraterone acetate) JOHNSON & JOHNSON HK Reg. No. HK-68296 (09 Jul, 2024) & HK-68295 (09 Jul, 2024) Composition: 2 AKEEGA™ is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, an...
LITFULO™ (ritlecitinib) PFIZER HK Reg. No. HK-68283 (28 Jun, 2024) Composition: 4 LITFULO™ is a kinase inhibitor available in the form of capsule with 50 mg ritlecitinib. Indication: 4 LITFULO™ is indicated for the treatment of sev...
Coronary artery disease (CAD) is a significant health challenge, imposing substantial burdens on individuals and healthcare systems worldwide. Notably, in Hong Kong, 1.6% of those aged 15 or above are reported as doctor-diagnosed CAD, with a higher ...
